We herein report a case of Hashimoto's thyroiditis (HT) with sequential autoimmune hepatitis (AIH), chorea and polyserositis. The patient was a 24-year-old man who underwent subtotal thyroidectomy due to compression symptoms caused by goiter and was diagnosed with HT postoperatively based on pathological examinations two years previously. He had exhibited liver dysfunction and intermittent chorea since 2008. His liver function and polyserositis improved remarkably following the administration of ursodeoxycholic acid (UDCA) and methylprednisolone. This is a very rare case that can be classified as autoimmune polyglandular syndrome (APS) type 3. Early and adequate UDCA and glucocorticoid treatment may lead to a favorable prognosis.
Introduction
Autoimmune involvement of multiple organs is defined as autoimmune polyglandular syndrome (APS). Autoimmune thyroid diseases (AITD), including Hashimoto's thyroiditis (HT), are common organ-specific autoimmune diseases that frequently coexist with other autoimmune disorders (1) (2) (3) . Autoimmune hepatitis (AIH) is a disease of progressive destruction of the hepatic parenchyma leading to intrahepatic cholestasis and cirrhosis of unknown etiology (4) . We herein report a case of HT accompanied by AIH confirmed on a liver biopsy, although all AIH-related autoimmune antibodies were negative. Polyserositis and chorea were the other striking features of this illness. After treatment with ursodeoxycholic acid (UDCA) and methylprednisolone, the symptoms and laboratory data subsequently improved dramatically. On the basis of this case report, we suggest that AIH, AITD, chorea and polyserositis might share a common immunologic pathway in disease pathogenesis. Early and adequate UDCA and glucocorticoid treatment may lead to a favorable prognosis.
Case Report
In June 2011, a 24-year-old man was admitted to our hospital with symptoms of asthenia, dyspnea, lower extremity edema and intermittent chorea. He had undergone subtotal thyroidectomy due to compression symptoms caused by goiter two years previously. He was diagnosed with HT and administered synthetic thyroxine (120 μg bid) postoperatively. Unfortunately, hepatic dysfunction of an unknown cause occurred. Furthermore, the patient had been diagnosed with chorea and distal involuntary movements approximately three years previously. He had no history of traveling abroad and no alcohol or smoking addictions. None of his firstdegree relatives had suffered from any autoimmune diseases.
The present findings were as follows: blood pressure, 96/ Figure. Histological findings of liver biopsy specimen revealed lymphocytes and plasma cells accumulated in the portal areas with fibrous expansion and periportal necrosisand and bile duct was damaged. Hematoxylin and Eosin staining, ×200. 
negative -60 mmHg; body temperature, 37.0 ; pulse,130 beats/min and regular; respiratory rate, 20 breaths/min; palpebral conjunctiva, not anemic; conjunctiva bulbi, icteric; neck, scar; thyroid gland, slightly enlarged without tenderness; cardiac boundary, enlarged; chest auscultation, low bilateral lung respiratory sounds; heart sounds, low and dull; abdomen, abdominal distension; liver and spleen, palpable at the subcostal area; bowel sounds, nothing particular; lower extremity edema; and skin, negative for jaundice. No flapping tremors or palmar erythema were observed. No superficial lymph nodes were palpable. Table shows the results of blood chemistry and immunological tests performed on admission and after methylprednisolone treatment. A bone marrow aspiration smear revealed nucleated cell hyperplasia hyperactivity, although no obvious erythrocyte abnormalities were observed. Moderate amounts of pleural effusion and ascites and a massive amount of pericardial effusion were detected on B ultrasonography. Electroencephalography (EEG) and cerebral magnetic resonance imaging (MRI) findings were both normal. The serum cortisol concentration was normal.
The administration of thyroxine replacement therapy, diuretics and UDCA (600 mg daily) was started after admission. Consequently, the lower extremity edema was gradually alleviated. The alkaline phosphatase (ALP) level decreased to 1,974 IU/L and the γ-Glutamyl transpeptidase (γ-GT) level decreased to 578 IU/L; however, no significant changes were observed in the pericardial effusion, pleural effusion or ascites. The fluid drawn with thoracentesis and pericardiocentesis was clear to straw-colored in appearance without bacteria, blood, cancer cells or tuberculosis, which indicated an exudate.
Figure shows the histology of the liver biopsy. A pathological examination revealed lymphocytes and plasma cells accumulated in the portal areas with fibrous expansion, periportal necrosis and damaged bile ducts. All of the above findings led to a diagnosis of AIH.
Intravenous methylprednisolone at a dose of 80 mg daily was administered for 15 days after the liver biopsy. The dose of methylprednisolone was then reduced to 60 mg daily for seven days. The laboratory data subsequently im- The patient was discharged after his laboratory data improved and his symptoms of asthenia, dyspnea and involuntary movements were alleviated. Oral prednisone (20 mg daily) and synthetic thyroxine (120 μg bid) treatments were maintained after discharge.
Discussion
APS was initially defined as a multiple endocrine gland insufficiency associated with autoimmune disease. The associations between the diseases in APS have been noted to not be random, but rather to occur in particular combinations, with the inclusion of some nonendocrine autoimmune diseases. APS includes four subtypes: APS-1, APS-2, APS-3 and APS-4. In the original classification by Neufeld (5), APS-3 was characterized as AITD concomitant with other autoimmune syndromes (i.e., endocrine in type 3a; gastrointestinal and liver in type 3b; skin, hemopoietic and nervous system in type 3c; and other unspecified diseases in type 3d). The coexistence of HT, AIH, chorea and polyserositis in the present 24-year-old man confirmed the diagnosis of APS-3. In general, severe hypothyroidism or hypoproteinemia may lead to polyserositis. Nevertheless, the patient's thyroid function parameters and plasma albumin concentration were near the lower limits, which would not lead to polyserositis. After the administration of moderate-dose methylprednisolone therapy, the patient's pericardial effusion, pleural effusion and ascites gradually disappeared. We considered that the polyserositis may have occurred due to autoimmunity. Therefore, we suggest that polyserositis maybe a component of APS. In addition, chorea is a rare nervous system disease involving clinical manifestations of involuntary, forcible, rapid, jerky movements. The pathogenesis results from autoimmune injury of the basal ganglia without a clear underlying mechanism. It was concluded that the characteristics of APS 3b and 3c overlapped in this case.
Hashimoto's encephalopathy (HE) is a neurological disorder of unknown cause associated with thyroid autoimmunity. The clinical manifestations of HE usually include uncontrolled seizures and psychosis, similar to the symptoms of chorea. The mechanism underlying HE does not appear to be related to thyroid status, which can vary greatly in patients with HE. In two reviews, 23% to 35% of patients had subclinical hypothyroidism, 17% to 20% had hypothyroidism, 7% had hyperthyroidism and 18% to 45% were euthyroid (6, 7) . In a review of 82 patients with HE, brain computed tomography and MRI showed abnormalities such as cerebral atrophy, focal cortical abnormalities, diffuse subcortical abnormalities and nonspecific subcortical focal white matter abnormalities in 49% of the patients (7). In our patient, although the brain MRI findings were normal, we cannot completely rule out the possibility that the chorea was a symptom of HE.
Biochemical and immunoserological measurements were obtained in this case. The levels of transaminases, as well as those of biliary tract enzymes, were already elevated, and the lack of hepatitis virus infection or drugs that may have been causative led us to suspect the existence of cholangitis and hepatocyte injury brought about through an autoimmune mechanism. In the present patient, anti-smooth muscle antibody (ASMA), antimitochondrial antibody (AMA) and antinuclear antibody (ANA), etc. were all found to be negative using the immunofluorescence (IF) method. A liver biopsy revealed lymphocytes and plasma cells in the portal areas with fibrous expansion, periportal necrosis and damaged bile ducts, which led to the diagnosis of AIH. It has been reported that ANA, the traditional marker of AIH, is positive alone (13%) or in conjunction with ASMA (54%) in 67% of AIH patients (8) . ASMA, another standard marker of AIH, is directed against actin and nonactin components, including tubulin, vimentin, desmin and skeletin (9) . ASMA is present in 87% of patients with AIH, either as the sole marker of the disease (33%) or in conjunction with ANA (54%) (8) . However, all AIH-related antibodies were negative in the present patient. To confirm the diagnosis and select further treatment strategies, a liver biopsy and pathological examinations were conducted. Daniel et al. (10) described six seronegative AIH patients. These patients, who had no detectable autoantibody markers, were very similar to conventional AIH patients. Liver biopsies excluded nonalcoholic steatohepatitis in all patients and demonstrated moderately to severely active interface hepatitis. Treatment with corticosteroids (prednisone) resulted in rapid biochemical improvement in all patients. Our patient is very similar to these patients and most likely could be classified with seronegative AIH.
It has been reported that UDCA is effective for AIH treatment. UDCA at a dose of 600 mg daily was initially administered to our patient. Indeed, it was effective in improving the results of blood tests for a relatively long period. However, when polyserositis appeared, corticosteroid therapy was very effective, whereas no other drugs improved the ALT and AST levels. Treatment with methylprednisolone at a dose of 80 mg daily for 15 days almost normalized the transaminase and bilirubin levels and alleviated the polyserositis. Ben Ari et al. (11) reported the efficacy of steroid therapy in three patients with autoimmune cholangiopathy. It has been proven histologically that steroid administration attenuates infiltration of inflammatory cells in portal areas and liver parenchyma as well as reducing periportal necrosis. Approximately 90% of adults show improvements in the serum aminotransferase, bilirubin and γ-GT levels within two weeks of starting prednisone therapy (12) .
In summary, this patient was diagnosed with AIH based on a histological examination of a liver biopsy and negative ASMA and ANA findings. This extremely rare case suggests that AIH, AITD, chorea and polyserositis might share a common immunogenetic pathway in the pathogenesis of APS. Early and appropriate treatment with UDCA and glucocorticoids may therefore lead to a better prognosis in such cases.
